Skip NavigationSkip to Content

Clonal hematopoiesis in people with advanced HIV and associated inflammatory syndromes

  1. Author:
    Rocco, Joseph M
    Zhou, Yifan
    Liu, Nicholas S
    Laidlaw, Elizabeth
    Galindo, Frances
    Anderson, Megan V
    Rupert,Adam
    Lucena Lage, Silvia
    Ortega-Villa, Ana M
    Yu, Shiqin
    Lisco, Andrea
    Manion, Maura
    Vassiliou, George S
    Dunbar, Cynthia E
    Sereti, Irini
  2. Author Address

    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America., Translational Stem Cell Biology Branch, National Heart, Lung and Blood Inst, NIH, Bethesda, United States of America., Leidos Biomedical Research Core, Frederick, United States of America., Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.,
    1. Year: 2024
    2. Date: Apr 02
    3. Epub Date: 2024 04 02
  1. Journal: JCI Insight
    1. 9
    2. 9
  2. Type of Article: Article
  3. Article Number: e174783
  1. Abstract:

    People with HIV (PWH) have a higher age-adjusted mortality due to chronic immune activation and age-related comorbidities. PWH also have higher rates of clonal hematopoiesis (CH) than age-matched non-HIV cohorts, however, risk factors influencing the development and expansion of CH in PWH remain incompletely explored. We investigated the relationship between CH, immune biomarkers, and HIV-associated risk factors (CD4, CD8 T-cells, nadir CD4 count, opportunistic infections [OIs], and immune reconstitution inflammatory syndrome [IRIS]) in a diverse cohort of 197-PWH with median age of 42-years, using a 56-gene panel. Seventy-nine percent had a CD4 nadir < 200, 58.9% had prior OIs, and 34.5% had a history of IRIS. The prevalence of CH was high (27.4%), even in younger individuals, and CD8 T-cells and nadir CD4 counts strongly associated with CH after controlling for age. A history of IRIS was associated with CH in a subgroup analysis of = 35-years-old patients. Inflammatory biomarkers were higher in CH carriers compared to non-carriers supporting a dysregulated immune state. These findings suggest PWH with low nadir CD4 and/or inflammatory complications may be at high risk of CH regardless of age and represent a high-risk group that could benefit from risk reduction and potentially targeted immunomodulation.

    See More

External Sources

  1. DOI: 10.1172/jci.insight.174783
  2. PMID: 38564303
  3. PMCID: PMC11141903
  4. WOS: 001223274600001
  5. PII : 174783

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel